Drug Formulary Review articles from January 2006

Drug Formulary Review archives from January 2006

Applying evidence-based medicine to formulary decisions.
January 1, 2006... Applying evidence-based medicine to formulary decisions Pharmacists adjust criteria to evaluate conflicting trial data "Evidence-based" is one term often heard at the ASHP meeting. In one presentation, "Applying the principles of...

ASHP Foundation announces research results.
January 1, 2006... ASHP Foundation announces research results At the midyear meeting, several researchers spoke about their Foundation-funded research projects. Here are preliminary details of two of them. • Medication errors and adverse drug events...

ENH wins medication-use safety award.
January 1, 2006... ENH wins medication-use safety award The ASHP Foundation has announced that Evanston (IL) Northwestern Healthcare (ENH) has been awarded the 2005 Award for Excellence in Medication-Use Safety. This award program honors a pharmacist-led...

Research News.
January 1, 2006... Mycophenolate mofetil (CellCept) shows promise in treating lupus. New research shows promising results in the use of mycophenolate mofetil (CellCept) to treat lupus — without severe side effects associated with the current standard of...

News Briefs.(mesh brief)
January 1, 2006... Falsely elevated glucose readings, warns FDA The FDA has notified pharmacists, physicians, nurses, medical technologists, pharmacists, and other health care professionals of the potential for life-threatening falsely elevated glucose...

New FDA Approvals.(food and drug administration)
January 1, 2006... These drugs were recently approved by the FDA: • Deferasirox (Exjade) by Novartis Pharmaceutical Corp. The FDA has approved deferasirox (Exjade), an oral iron chelator developed to treat chronic iron overload due to multiple blood...

In The Pipeline.
January 1, 2006... • SGX Pharmaceuticals has announced that Troxatyl, an investigational drug in a pivotal Phase II/III clinical trial, has been granted fast track designation by the FDA for third-line treatment of acute myeloid leukemia in adults. ...

Drug Criteria & Outcomes: Ramelteon (Rozerem) Formulary Evaluation.(for the treatment of insomnia)
January 1, 2006... Drug Criteria & Outcomes Ramelteon (Rozerem) Formulary Evaluation By Patrick J. Phillips, PharmD Candidate McWhorter School of Pharmacy, Samford University Birmingham, AL Description Ramelteon (Rozerem) is an orally active...

CE objectives/questions.(clinical efficacy)(Brief Article)
January 1, 2006... CE Objectives/Questions This CE program will improve participants' ability to: *Compare the clinical efficacy and safety of one therapeutic agent over another used in the same setting. *Assess clinical trial data and explain how...